
  
    
      
        Background_NNP
        There_RB are_VBP over_IN 450_CD telemedicine_NN programs_NNS worldwide_NN ,_, with_IN
        over_IN 360_CD of_IN those_DT in_IN the_DT United_NNP States_NNPS [_NN 1_CD ]_NN ._. There_EX are_VBP
        programs_NNS in_IN virtually_RB every_DT medical_JJ specialty_NN ,_, and_CC the_DT
        populations_NNS they_PRP most_RBS commonly_RB serve_VB include_VBP those_DT who_WP live_VBP
        in_IN rural_JJ areas_NNS ,_, the_DT elderly_JJ ,_, and_CC veterans_NNS ._. With_IN the_DT growing_VBG
        ability_NN of_IN modern_JJ computer_NN and_CC communications_NNS technology_NN to_TO
        capture_VB and_CC quickly_RB transmit_VB textual_NN ,_, audio_JJ ,_, and_CC video_NN
        information_NN ,_, many_JJ have_VBP advocated_VBN its_PRP$ use_NN to_TO improve_VB the_DT
        health_NN care_NN provided_VBN to_TO individuals_NNS in_IN rural_JJ areas_NNS ,_, in_IN the_DT
        home_NN ,_, and_CC in_IN other_JJ places_NNS where_WRB medical_JJ personnel_NNS are_VBP not_RB
        readily_RB available_JJ ._.
        Many_JJ believe_VBP that_IN the_DT growth_NN of_IN telemedicine_NN is_VBZ impeded_VBN
        by_IN reimbursement_NN policies_NNS of_IN the_DT federal_JJ government_NN and_CC
        private_JJ insurers_NNS [_NN 2_CD 3_CD ]_NN ._. These_DT authors_NNS claim_VBP this_DT leads_VBZ
        to_TO a_DT vicious_JJ cycle_NN :_: There_EX is_VBZ a_DT growing_VBG call_NN for_IN
        telemedicine_NN services_NNS to_TO be_VB covered_VBN as_IN part_NN of_IN health_NN
        insurance_NN ._. Health_NN care_NN payors_NNS ,_, whether_IN governmental_JJ or_CC
        private_JJ ,_, have_VBP been_VBN reluctant_JJ to_TO do_VB so_RB ._. This_DT ,_, in_IN turn_NN ,_, has_VBZ
        led_VBN telemedicine_NN advocates_NNS to_TO blame_VB payors_NNS for_IN impeding_VBG
        development_NN of_IN the_DT technology_NN ._.
        One_CD reason_NN for_IN the_DT lack_NN of_IN coverage_NN of_IN telemedicine_NN has_VBZ
        been_VBN an_DT uncertainty_NN about_IN its_PRP$ efficacy_NN and_CC cost_NN ._. There_EX have_VBP
        been_VBN a_DT number_NN of_IN previous_JJ systematic_JJ reviews_NNS assessing_VBG the_DT
        efficacy_NN of_IN telemedicine_NN and_CC related_VBN technologies_NNS [_NN 4_CD 5_CD 6_CD 7_CD
        8_CD 9_CD ]_NN ._. All_DT of_IN these_DT studies_NNS noted_VBD that_IN although_IN the_DT
        technology_NN showed_VBD promise_NN in_IN certain_JJ areas_NNS ,_, the_DT overall_JJ
        methodologic_JJ quality_NN of_IN the_DT evaluative_JJ studies_NNS was_VBD low_JJ and_CC
        the_DT plan_NN for_IN the_DT most_RBS appropriate_JJ and_CC cost-effective_JJ use_NN of_IN
        telemedicine_NN was_VBD unclear_JJ ._.
        This_DT systematic_JJ review_NN had_VBD its_PRP$ origins_NNS in_IN a_DT report_NN
        commissioned_VBN by_IN the_DT US_NNP Health_NNP Care_NNP Financing_NNP Agency_NNP (_( HCFA_NNP )_)
        and_CC the_DT Agency_NNP for_IN Healthcare_NNP Research_NNP and_CC Quality_NNP (_( AHRQ_NNP )_)
        to_TO assess_VB the_DT efficacy_NN of_IN telemedicine_NN in_IN the_DT adult_NN ,_,
        non-pregnant_JJ population_NN [_NN 1_CD ]_NN ._. A_DT subsequent_JJ supplemental_JJ
        report_NN extended_VBD the_DT analysis_NN to_TO the_DT pediatric_JJ and_CC obstetric_JJ
        population_NN [_NN 10_CD ]_NN ._. The_DT goal_NN of_IN this_DT paper_NN is_VBZ to_TO assess_VB
        whether_IN telemedicine_NN interventions_NNS result_VBP in_IN comparable_JJ
        health_NN outcomes_NNS to_TO in-person_JJ care_NN ._. It_PRP merges_NNS results_NNS from_IN
        the_DT original_JJ two_CD reports_NNS and_CC updating_VBG them_PRP with_IN studies_NNS
        published_VBN since_IN the_DT reports_NNS were_VBD submitted_VBN to_TO the_DT federal_JJ
        agencies_NNS ._.
        We_PRP broadly_RB divide_VBP telemedicine_NN into_IN two_CD general_JJ areas_NNS ._.
        In_IN 
        office_NN /_NN hospital-based_JJ
        telemedicine_NN ,_, both_DT the_DT patient_NN and_CC clinician_NN are_VBP in_IN a_DT
        professional_JJ health_NN care_NN setting_NN ,_, such_JJ as_IN a_DT practitioner_NN 's_POS
        office_NN or_CC in_IN the_DT hospital_NN ._. There_EX is_VBZ a_DT subcategory_NN of_IN
        office_NN /_NN hospital-based_JJ telemedicine_NN called_VBD 
        store-and-forward_JJ telemedicine_NN ,_, where_WRB
        clinical_JJ data_NNS is_VBZ collected_VBN and_CC forwarded_JJ for_IN review_NN later_RB
        in_IN a_DT completely_RB asynchronous_JJ manner_NN ,_, but_CC it_PRP was_VBD not_RB
        assessed_VBN in_IN this_DT systematic_JJ review_NN because_IN our_PRP$ literature_NN
        review_NN failed_VBD to_TO identify_VB any_DT studies_NNS of_IN clinical_JJ outcomes_NNS
        utilizing_VBG it_PRP ._. In_IN 
        home-based_JJ telemedicine_NN ,_, the_DT patient_NN
        is_VBZ at_IN his_PRP$ or_CC her_PRP$ residence_NN ,_, with_IN direct_JJ communication_NN
        between_IN the_DT clinician_NN and_CC the_DT patient_NN or_CC their_PRP$
        caregiver_NN ._.
      
      
        Methods_NNP
        The_DT criteria_NNS for_IN study_NN inclusion_NN in_IN this_DT systematic_JJ
        review_NN were_VBD that_IN the_DT study_NN be_VB relevant_JJ to_TO at_IN least_JJS one_CD of_IN
        the_DT areas_NNS of_IN telemedicine_NN and_CC contain_VB data_NNS on_IN outcomes_NNS of_IN
        clinical_JJ care_NN that_WDT compared_VBD telemedicine_NN with_IN a_DT control_NN
        group_NN of_IN in-person_JJ care_NN ._. We_PRP excluded_VBD services_NNS that_WDT would_MD
        not_RB normally_RB require_VB face-to-face_JJ encounters_NNS between_IN the_DT
        clinician_NN and_CC patient_NN (_( e_SYM ._. g_SYM ._. ,_, radiology_NN and_CC pathology_NN
        diagnosis_NN )_) ,_, used_VBD only_RB telephone_NN care_NN or_CC electronic_JJ mail_NN ,_, or_CC
        provided_VBD medical_JJ advice_NN directly_RB to_TO the_DT public_NN ._.
        We_PRP developed_VBD a_DT search_NN strategy_NN designed_VBN to_TO find_VB any_DT
        publications_NNS about_IN telemedicine_NN and_CC used_VBD it_PRP to_TO search_VB
        MEDLINE_NNP ,_, EMBASE_NNP ,_, CINAHL_NNP ,_, and_CC HealthSTAR_NNP through_IN February_NNP ,_,
        2001_CD (_( see_VB Figure_NN 1_LS )_) ._. We_PRP also_RB searched_VBD through_IN telemedicine_NN
        reports_NNS and_CC compilations_NNS such_JJ as_IN the_DT 
        Conseil_NNP d_SYM '_POS Evaluation_NNP des_NNP Technologies_NNPS de_IN
        la_FW Sante_NNP du_NNP Quebec_NNP [_NN 11_CD ]_NN ,_, the_DT 
        Telemedicine_NNP Strategic_NNP Healthcare_NNP Group_NNP
        Report_NNP ,_, [_NN 12_CD ]_NN the_DT 
        International_NNP Society_NNP for_IN Telemedicine_NNP
        Conference_NNP Proceedings_NNP ,_, the_DT Association_NNP of_IN Telemedicine_NNP
        Service_NNP Providers_NNP '_POS database_NN [_NN 13_CD ]_NN ,_, and_CC the_DT 
        Telemedicine_NNP Sourcebook_NNP 1998_CD [_NN 14_CD ]_NN ._.
        We_PRP also_RB assessed_VBD three_CD systematic_JJ reviews_NNS (_( different_JJ in_IN
        scope_NN from_IN this_DT study_NN )_) from_IN the_DT International_NNP Network_NNP of_IN
        Agencies_NNPS for_IN Health_NNP Technology_NNP (_( INHATA_NNP )_) [_NN 5_CD ]_NN ,_, the_DT
        Cochrane_NNP Database_NNP of_IN Systematic_NNP Reviews_NNP [_NN 7_CD ]_NN ,_, and_CC the_DT
        Agenda_NN d_SYM '_POS Avaluacio_NNP de_IN Technologia_NNP Medica_NNP [_NN 6_CD ]_NN ._. In_IN
        addition_NN ,_, we_PRP identified_VBD additional_JJ articles_NNS from_IN the_DT
        reference_NN lists_NNS of_IN included_VBD reports_NNS and_CC articles_NNS and_CC also_RB
        contacted_VBN known_VBN telemedicine_NN experts_NNS to_TO find_VB additional_JJ
        articles_NNS to_TO identify_VB and_CC describe_VB telemedicine_NN programs_NNS ._.
        Finally_RB ,_, we_PRP also_RB handsearched_JJ all_DT issues_NNS of_IN the_DT two_CD major_JJ
        telemedicine_NN journals_NNS ,_, 
        Journal_NNP of_IN Telemedicine_NNP and_CC
        Telecare_NNP and_CC 
        Telemedicine_NNP Journal_NNP (_( recently_RB
        renamed_VBN 
        Telemedicine_NNP Journal_NNP and_CC e-_NN Health_NNP )_) ,_,
        through_IN the_DT end_NN of_IN 2000_CD ._.
        Each_DT title_NN /_NN abstract_JJ retrieved_VBD was_VBD reviewed_VBN by_IN two_CD
        reviewers_NNS ._. When_WRB the_DT two_CD reviewers_NNS disagreed_VBD ,_, a_DT third_JJ
        reviewer_NN made_VBD the_DT final_JJ decision_NN ._. We_PRP retrieved_VBD the_DT
        full-text_JJ articles_NNS for_IN citations_NNS selected_VBN for_IN possible_JJ
        inclusion_NN in_IN the_DT systematic_JJ review_NN ._. When_WRB an_DT article_NN met_VBD the_DT
        criteria_NNS for_IN inclusion_NN ,_, the_DT summary_NN statistics_NNS were_VBD
        extracted_VBN ._. To_TO evaluate_VB the_DT quality_NN of_IN the_DT studies_NNS assessed_VBN ,_,
        we_PRP adapted_VBD a_DT scale_NN developed_VBN by_IN our_PRP$ evidence-based_JJ practice_NN
        center_NN (_( Table_NNP 1_LS )_) [_NN 15_CD ]_NN ._. We_PRP used_VBD a_DT second_JJ scale_NN to_TO
        indicate_VB the_DT direction_NN of_IN the_DT evidence_NN (_( Table_NNP 2_LS )_) ._.
      
      
        Results_NNS
        
          Home-based_NNP telemedicine_NN
          
            Diabetes_NNP Mellitus_NNP
            The_DT studies_NNS that_WDT have_VBP assessed_VBN home_NN monitoring_NN of_IN
            diabetes_NN have_VBP focused_VBN on_IN tracking_VBG insulin_NN dosages_NNS and_CC
            used_VBN Hemoglobin_NNP A_DT 1_CD C_NNP as_IN an_DT outcome_NN measure_NN ._. Two_CD of_IN the_DT
            studies_NNS identified_VBN focused_VBN on_IN gestational_JJ diabetes_NN ,_, one_CD
            on_IN children_NNS ,_, and_CC the_DT remainder_NN on_IN adults_NNS ._. Only_RB one_CD
            diabetes_NN study_NN was_VBD adequately_RB designed_VBN to_TO rate_NN as_IN a_DT
            class_NN I_PRP randomized_JJ controlled_VBN trial_NN (_( RCT_NNP )_) [_NN 16_CD ]_NN ._. This_DT
            pediatric_JJ study_NN showed_VBD no_DT difference_NN in_IN glycemic_JJ
            control_NN between_IN groups_NNS (_( HgbA_NNP 1_CD C_NNP for_IN both_DT groups_NNS actually_RB
            rose_VBD )_) ,_, emergency_NN room_NN visits_NNS ,_, psychological_JJ status_NN ,_, and_CC
            family_NN functioning_NN ._.
            The_DT two_CD largest_JJS studies_NNS of_IN adults_NNS showed_VBD that_IN both_DT
            the_DT experimental_JJ and_CC control_NN groups_NNS improved_VBN ,_, with_IN no_DT
            statistically_RB significant_JJ difference_NN between_IN them_PRP [_NN 17_CD
            18_CD ]_NN ._. Three_CD other_JJ studies_NNS demonstrated_VBD a_DT small_JJ but_CC
            statistically_RB significant_JJ benefit_NN in_IN HgbA_NNP 1_CD C_NNP [_NN 19_CD 20_CD 21_CD
            ]_NN ._.
            Both_DT studies_NNS of_IN home_NN gestational_JJ diabetes_NN monitoring_VBG
            found_VBN improvements_NNS in_IN blood_NN sugar_NN values_NNS but_CC not_RB in_IN
            HgbA_NNP 1_CD C_NNP ,_, although_IN each_DT had_VBN very_RB small_JJ sample_NN sizes_NNS and_CC
            probable_JJ inadequate_JJ statistical_JJ power_NN to_TO detect_VB a_DT
            difference_NN [_NN 22_CD 23_CD ]_NN ._.
          
          
            General_NNP Chronic_NNP Disease_NNP Management_NNP
            Three_CD studies_NNS addressed_VBD general_JJ chronic_JJ disease_NN
            management_NN ._. The_DT largest_JJS and_CC best-designed_JJ was_VBD an_DT RCT_NNP
            where_WRB both_DT the_DT intervention_NN and_CC control_NN groups_NNS were_VBD
            provided_VBN usual_JJ home_NN health_NN care_NN but_CC the_DT intervention_NN
            group_NN also_RB received_VBD a_DT video_NN system_NN that_WDT allowed_VBD
            real-time_JJ remote_JJ interaction_NN with_IN the_DT health_NN system_NN [_NN
            24_CD ]_NN ._. Both_DT groups_NNS had_VBD comparable_JJ compliance_NN with_IN
            medication_NN regimen_NN ,_, knowledge_NN about_IN their_PRP$ disease_NN ,_,
            ability_NN to_TO move_VB toward_IN self-care_JJ ,_, and_CC scores_NNS on_IN the_DT
            12_CD -_: item_NN Short-_NNP Form_NNP Health_NNP Survey_NNP (_( SF-_NNP 12_CD )_) ™_NN ._.
            The_DT other_JJ studies_NNS described_VBD the_DT use_NN of_IN videophones_NNS
            for_IN patient_NN communication_NN with_IN health_NN care_NN providers_NNS ._.
            In_IN a_DT study_NN in_IN Japan_NNP ,_, 16_CD elderly_JJ patients_NNS who_WP were_VBD
            provided_VBN with_IN videophones_NNS were_VBD compared_VBN to_TO 16_CD matched_VBN
            patients_NNS who_WP used_VBD regular_JJ home_NN health_NN services_NNS [_NN 25_CD ]_NN ._.
            After_IN 3_CD months_NNS ,_, the_DT videophone_NN group_NN significantly_RB
            exceeded_VBD the_DT control_NN group_NN in_IN activities_NNS of_IN daily_JJ
            living_NN ,_, communications_NNS ,_, and_CC social_JJ cognition_NN ,_, as_IN
            measured_VBN with_IN the_DT Functional_NNP Independence_NNP Measure_NN ._. The_DT
            videophone_NN intervention_NN was_VBD a_DT supplement_NN to_TO (_( not_RB a_DT
            substitute_NN for_IN )_) regular_JJ home_NN health_NN services_NNS ._. The_DT
            second_JJ study_NN ,_, a_DT qualitative_JJ report_NN of_IN 12_CD cases_NNS ,_, showed_VBD
            a_DT reduction_NN in_IN the_DT number_NN of_IN home-care_JJ visits_NNS needed_VBN
            for_IN seven_CD of_IN the_DT patients_NNS [_NN 26_CD ]_NN ._.
          
          
            Hypertension_NNP
            Of_IN the_DT two_CD studies_NNS of_IN monitoring_VBG hypertension_NN via_IN
            home-based_JJ telemedicine_NN ,_, one_CD looked_VBD at_IN the_DT elderly_JJ
            while_IN the_DT other_JJ looked_VBD at_IN pregnant_JJ women_NNS ._. The_DT study_NN of_IN
            the_DT elderly_JJ was_VBD an_DT RCT_NNP that_WDT assessed_VBD the_DT effect_NN of_IN a_DT
            computer-controlled_JJ ,_, automated_VBN telephone_NN system_NN versus_CC
            usual_JJ office-based_JJ care_NN on_IN adherence_NN and_CC blood_NN pressure_NN
            control_NN in_IN older_JJR hypertensive_JJ patients_NNS [_NN 27_CD ]_NN ._. Mean_VB
            antihypertensive_JJ medication_NN adherence_NN improved_VBD 17_CD ._. 7_CD
            percent_NN for_IN telephone_NN system_NN users_NNS versus_CC 11_CD ._. 7_CD percent_NN
            for_IN controls_NNS ._. Mean_VB diastolic_JJ blood_NN pressure_NN decreased_VBD
            5_CD ._. 2_CD mm_NN Hg_NNP in_IN users_NNS compared_VBN to_TO a_DT 0_CD ._. 8_CD mm_NN Hg_NNP drop_NN in_IN
            controls_NNS ,_, a_DT statistically_RB significant_JJ difference_NN ._. There_EX
            was_VBD also_RB a_DT positive_JJ relationship_NN between_IN medication_NN
            adherence_NN and_CC blood_NN pressure_NN reduction_NN ._. The_DT study_NN of_IN
            hypertension_NN in_IN pregnant_JJ women_NNS found_VBD that_IN an_DT at-home_JJ
            blood_NN pressure_NN monitoring_VBG system_NN resulted_VBD in_IN comparable_JJ
            levels_NNS of_IN blood_NN pressure_NN ,_, anxiety_NN ,_, and_CC gestational_JJ age_NN
            of_IN delivery_NN as_IN hospital-based_JJ monitoring_NN [_NN 28_CD ]_NN ._.
          
          
            AIDS_NNP
            Two_CD studies_NNS of_IN persons_NNS with_IN AIDS_NNP demonstrated_VBD the_DT
            value_NN of_IN a_DT home_NN computer_NN link_NN to_TO information_NN ,_, others_NNS
            with_IN the_DT disease_NN ,_, and_CC a_DT health_NN care_NN professional_JJ who_WP
            could_MD steer_VB the_DT patient_NN to_TO advice_NN ._. One_CD of_IN the_DT studies_NNS
            showed_VBD the_DT system_NN reduced_VBD social_JJ isolation_NN after_IN
            controlling_VBG for_IN depression_NN as_RB well_RB as_IN improved_VBN
            decision-making_NN confidence_NN [_NN 29_CD ]_NN ._. The_DT other_JJ
            demonstrated_VBN various_JJ quality-of-life_JJ improvements_NNS as_RB
            well_RB as_IN fewer_JJR and_CC shorter_JJR hospitalizations_NNS [_NN 30_CD ]_NN ._.
          
          
            Other_JJ areas_NNS
            The_DT remaining_VBG studies_NNS provided_VBD evidence_NN of_IN benefit_NN
            in_IN a_DT variety_NN of_IN areas_NNS :_:
            •_NN An_DT RCT_NNP of_IN a_DT home_NN computer_NN link_NN for_IN caregivers_NNS of_IN
            patients_NNS with_IN Alzheimer_NNP 's_POS Disease_NNP found_VBD improved_VBN
            decision-making_NN confidence_NN [_NN 31_CD ]_NN ._.
            •_NN An_DT RCT_NNP of_IN patients_NNS in_IN a_DT home-exercise_JJ program_NN
            using_VBG transtelephonic_JJ exercise_NN monitoring_VBG compared_VBN to_TO a_DT
            hospital-based_JJ program_NN improved_VBD cardiac_JJ function_NN by_IN a_DT
            similar_JJ amount_NN [_NN 32_CD ]_NN ._. (_( One_CD caveat_NN of_IN this_DT study_NN was_VBD
            that_IN it_PRP had_VBD such_JJ low_JJ statistical_JJ power_NN that_IN it_PRP would_MD
            not_RB be_VB likely_JJ to_TO detect_VB any_DT difference_NN between_IN the_DT two_CD
            interventions_NNS in_IN efficacy_NN or_CC in_IN complications_NNS even_RB if_IN
            they_PRP existed_VBD ._. )_)
            •_NN An_DT RCT_NNP of_IN an_DT Internet-based_NNP telemedicine_NN program_NN
            for_IN families_NNS of_IN children_NNS in_IN a_DT neonatal_NN intensive_JJ care_NN
            unit_NN found_VBD that_IN among_IN infants_NNS born_VBN with_IN weight_NN of_IN
            <_NN 1_CD ,_, 000_CD grams_NNS ,_, there_EX was_VBD a_DT trend_NN towards_IN shorter_JJR
            hospital_NN stays_VBZ [_NN 33_CD ]_NN ._.
            •_NN A_DT study_NN of_IN videophones_NNS for_IN pediatric_JJ home_NN
            ventilator_NN patients_NNS found_VBD that_IN the_DT number_NN of_IN
            unscheduled_JJ hospital_NN visits_NNS and_CC hospital_NN admission_NN days_NNS
            was_VBD reduced_VBN significantly_RB compared_VBN with_IN historical_JJ
            controls_NNS [_NN 34_CD ]_NN ._.
          
        
        
          Office_NN /_NN hospital-based_JJ telemedicine_NN
          The_DT six_CD studies_NNS assessing_VBG clinical_JJ outcomes_NNS from_IN
          interventions_NNS of_IN office_NN /_NN hospital-based_JJ telemedicine_NN were_VBD
          spread_VBN across_IN five_CD specialties_NNS ._. (_( We_PRP actually_RB identified_VBD
          another_DT study_NN that_WDT appeared_VBD to_TO be_VB a_DT preliminary_JJ report_NN of_IN
          another_DT study_NN in_IN the_DT group_NN [_NN 35_CD ]_NN ._. )_)
          Of_IN the_DT two_CD RCTs_NNP identified_VBD ,_, one_CD assessed_VBN outcomes_NNS in_IN
          patients_NNS entering_VBG an_DT emergency_NN department_NN who_WP were_VBD
          randomized_JJ to_TO in-person_JJ or_CC telemedicine_NN care_NN [_NN 36_CD ]_NN ._.
          There_EX were_VBD no_DT differences_NNS in_IN the_DT need_NN for_IN additional_JJ
          fellow-up_JJ care_NN or_CC return_NN to_TO the_DT emergency_NN room_NN (_( ER_NNP )_) ,_,
          showing_VBG that_DT telemedicine_NN was_VBD as_RB effective_JJ as_IN regular_JJ
          care_NN in_IN this_DT setting_VBG ._. Another_DT RCT_NNP assessed_VBD "_'' clinical_JJ
          outcome_NN ,_, "_'' which_WDT was_VBD defined_VBN as_IN the_DT need_NN to_TO have_VB a_DT
          follow-up_JJ appointment_NN with_IN a_DT hospital-based_JJ specialist_NN [_NN
          37_CD ]_NN ._. Interactive_NNP teledermatology_NN consultation_NN (_( 46_CD
          percent_NN )_) was_VBD found_VBN to_TO have_VB the_DT same_JJ rate_NN of_IN need_NN for_IN
          follow-up_JJ care_NN as_IN in-person_JJ consultation_NN (_( 45_CD percent_NN )_) ._. No_DT
          statistical_JJ analysis_NN of_IN the_DT differences_NNS was_VBD
          performed_VBN ._.
          A_DT time_NN series_NN cohort_NN study_NN demonstrated_VBN reduced_VBN
          mortality_NN ,_, complications_NNS ,_, and_CC length_NN of_IN stay_NN in_IN a_DT
          community_NN hospital_NN surgical_JJ intensive_JJ care_NN unit_NN (_( ICU_NNP )_)
          with_IN continuous_JJ intensivist_NN oversight_NN via_IN telemedicine_NN [_NN
          38_CD ]_NN ._. A_DT study_NN in_IN a_DT neonatal_NN ICU_NNP used_VBD a_DT retrospective_NN
          comparison_NN to_TO show_VB reduced_VBD length_NN of_IN stay_NN with_IN the_DT use_NN of_IN
          a_DT telecardiology_NN system_NN [_NN 39_CD ]_NN ._. Two_CD studies_NNS of_IN
          neurosurgery_NN patients_NNS demonstrated_VBD benefit_NN of_IN
          transmission_NN of_IN radio_NN logic_NN studies_NNS to_TO avert_VB
          complications_NNS in_IN patient_NN transfer_NN [_NN 40_CD 41_CD ]_NN ._.
        
      
      
        Discussion_NNP
        Despite_IN the_DT widespread_JJ use_NN of_IN telemedicine_NN in_IN virtually_RB
        all_DT areas_NNS of_IN health_NN care_NN delivery_NN ,_, there_EX is_VBZ only_RB a_DT small_JJ
        amount_NN of_IN evidence_NN that_IN interventions_NNS provided_VBN by_IN
        telemedicine_NN result_NN in_IN clinical_JJ outcomes_NNS are_VBP comparable_JJ to_TO
        or_CC better_JJR than_IN face-to-face_JJ care_NN ._. The_DT best_JJS evidence_NN comes_VBZ
        from_IN home-based_JJ telemedicine_NN ,_, where_WRB modest_JJ benefits_NNS have_VBP
        been_VBN shown_VBN for_IN patients_NNS with_IN chronic_JJ disease_NN ,_, AIDS_NNP ,_, and_CC
        Alzheimer_NNP 's_POS Disease_NNP ._. The_DT most_RBS studied_VBN area_NN in_IN home-based_JJ
        telemedicine_NN is_VBZ monitoring_NN of_IN blood_NN sugar_NN in_IN patients_NNS with_IN
        diabetes_NN mellitus_JJ ._. The_DT benefits_NNS are_VBP not_RB conclusive_JJ ,_, with_IN
        studies_NNS showing_VBG no_DT change_NN or_CC a_DT slight_JJ drop_NN in_IN HgbA_NNP 1_CD C_NNP
        levels_NNS ._.
        In_IN office_NN /_NN hospital-based_JJ telemedicine_NN ,_, there_EX is_VBZ good_JJ
        evidence_NN that_IN telemedicine_NN interventions_NNS provide_VBP comparable_JJ
        care_NN in_IN the_DT ER_NNP settings_NNS and_CC benefit_NN in_IN the_DT surgical_JJ and_CC
        neonatal_NN ICU_NNP settings_NNS ._. There_EX is_VBZ also_RB probable_JJ benefit_NN in_IN
        its_PRP$ use_NN prior_RB to_TO transfer_NN of_IN neurosurgery_NN patients_NNS ._.
        Although_IN there_EX is_VBZ good_JJ evidence_NN for_IN the_DT diagnostic_JJ
        capability_NN of_IN teledermatology_NN [_NN 1_CD ]_NN ,_, the_DT only_JJ assessment_NN
        of_IN its_PRP$ outcomes_NNS has_VBZ focused_VBN on_IN the_DT need_NN for_IN specialty_NN
        follow-up_JJ ._.
        Further_RB studies_VBZ must_MD be_VB done_VBN to_TO demonstrate_VB the_DT efficacy_NN
        of_IN telemedicine_NN for_IN diagnostic_JJ and_CC management_NN decisions_NNS ._.
        Large-scale_NNP RCTs_NNP must_MD be_VB done_VBN to_TO identify_VB the_DT health_NN
        outcomes_NNS whose_WP$ benefit_NN appears_VBZ most_RBS promising_JJ ._. If_IN the_DT goal_NN
        is_VBZ to_TO show_VB comparability_NN to_TO usual_JJ care_NN ,_, then_RB studies_VBZ must_MD
        provide_VB adequate_JJ statistical_JJ power_NN to_TO show_VB that_IN the_DT lack_NN of_IN
        a_DT difference_NN truly_RB exists_VBZ ._. Small_JJ studies_NNS with_IN inadequate_JJ
        power_NN are_VBP not_RB good_JJ evidence_NN ._. The_DT fact_NN that_DT telemedicine_NN is_VBZ
        an_DT emerging_VBG technology_NN is_VBZ not_RB a_DT reason_NN for_IN failing_VBG to_TO
        perform_VB appropriate_JJ evaluation_NN studies_NNS ._. Rather_RB ,_, new_JJ
        methodologies_NNS such_JJ as_IN "_'' tracker_NN trials_NNS "_'' should_MD be_VB used_VBN to_TO
        assess_VB it_PRP systematically_RB [_NN 42_CD ]_NN ._. Tracker_NNP trials_NNS are_VBP
        designed_VBN to_TO assess_VB new_JJ and_CC /_NN or_CC rapidly_RB changing_VBG
        interventions_NNS and_CC compare_VB efficacy_NN not_RB only_RB of_IN the_DT general_JJ
        intervention_NN but_CC also_RB specific_JJ instances_NNS of_IN it_PRP ,_, such_JJ as_IN a_DT
        newly-developed_JJ approach_NN that_WDT has_VBZ become_VBN available_JJ after_IN
        the_DT general_JJ trial_NN started_VBD ._. We_PRP would_MD also_RB advocate_VB that_IN
        journal_NN editors_NNS exhibit_NN restraint_NN when_WRB considering_VBG
        publication_NN of_IN low-quality_JJ evaluation_NN studies_NNS ._. As_IN such_JJ
        studies_NNS often_RB accompany_VB otherwise_RB appropriate_JJ descriptions_NNS
        of_IN telemedicine_NN systems_NNS ,_, they_PRP should_MD consider_VB refusing_VBG to_TO
        publish_VB the_DT portion_NN of_IN the_DT article_NN containing_VBG the_DT
        low-quality_JJ evaluation_NN study_NN and_CC publish_VB the_DT rest_NN ._.
        The_DT growth_NN of_IN high-speed_JJ telecommunications_NNS networks_NNS and_CC
        their_PRP$ ability_NN to_TO transmit_VB higher-quality_NN imaging_NN and_CC other_JJ
        clinical_JJ information_NN indicates_VBZ a_DT bright_JJ future_NN for_IN
        telemedicine_NN ,_, especially_RB as_IN the_DT infrastructure_NN is_VBZ built_VBN out_IN
        to_TO reach_VB to_TO individuals_NNS who_WP have_VBP historically_RB been_VBN denied_VBN
        high-quality_JJ health_NN care_NN due_JJ to_TO their_PRP$ remote_JJ location_NN ._. As_IN
        the_DT cost_NN of_IN these_DT services_NNS will_MD challenge_VB the_DT health_NN care_NN
        budgets_NNS of_IN even_RB well-to-do_JJ nations_NNS ,_, it_PRP is_VBZ imperative_JJ that_IN
        decisions_NNS to_TO use_VB them_PRP be_VB based_VBN on_IN appropriate_JJ evidence_NN that_IN
        they_PRP lead_VBP to_TO comparable_JJ patient_NN outcomes_NNS in_IN
        office_NN /_NN hospital-based_JJ telemedicine_NN and_CC improved_VBN patient_NN
        outcomes_NNS in_IN home-based_JJ telemedicine_NN ._.
      
      
        Disclaimer_NNP
        The_DT authors_NNS of_IN this_DT article_NN are_VBP responsible_JJ for_IN its_PRP$
        contents_NNS ,_, including_VBG any_DT clinical_JJ or_CC treatment_NN
        recommendations_NNS ._. No_DT statement_NN in_IN this_DT article_NN should_MD be_VB
        construed_VBN as_IN an_DT official_JJ position_NN of_IN the_DT Agency_NNP for_IN
        Healthcare_NNP Research_NNP and_CC Quality_NNP or_CC the_DT U_NNP ._. S_NNP ._. Department_NNP of_IN
        Health_NNP and_CC Human_NNP Services_NNPS ._.
      
      
        Competing_VBG Interests_NNP
        None_NN declared_VBD ._.
      
    
  
